4.8 Patient-Specific IMRT QA & In-Vivo Dosimetry Verification

4.8 Patient-Specific IMRT QA & In-Vivo Dosimetry Verification

Intensity-Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) deliver highly conformal dose distributions characterized by steep dose gradients, complex multi-leaf collimator (MLC) motion, dynamic gantry rotation, and rapid dose rate modulation. Because minor inaccuracies in MLC leaf positioning, small-field output factors, or treatment planning system (TPS) beam modeling can lead to severe dosimetric errors, Patient-Specific IMRT QA is clinically mandated for every IMRT/VMAT plan before the patient receives their first treatment fraction. Additionally, In-Vivo Dosimetry provides direct real-time measurement during treatment delivery.

Purpose and Clinical Mandate for Patient-Specific IMRT/VMAT QA

Unlike 3D conformal radiation therapy (where hand calculations or secondary independent software checks suffice to verify MU calculations), IMRT/VMAT delivery involves thousands of dynamic leaf sequences delivering non-uniform fluence fields. Secondary calculation software alone cannot fully account for physical machine delivery limitations such as MLC leaf speed limits, inter-leaf transmission, leaf end penumbra, or tongue-and-groove effects.

Patient-specific IMRT QA verifies that:

1. The TPS accurately calculates complex fluence profiles.
2. The linear accelerator control system correctly executes dynamic MLC drive files.
3. The delivered dose distribution matches the planned dose distribution within strict clinical tolerances.

Gamma Index Analysis Theory and Calculation

Evaluating agreement between a planned 2D/3D dose matrix and a measured dose matrix cannot rely solely on dose difference or spatial distance. In uniform dose regions (e.g., center of target), dose difference is sensitive, but Distance-to-Agreement (DTA) is meaningless. In steep dose gradient regions (e.g., target-OAR boundary), a 1 mm spatial shift can produce a 15% dose difference, making simple percentage difference misleading. Gamma Index Analysis ($\gamma$) solves this by mathematically combining percentage dose difference (%DD) and spatial distance-to-agreement (DTA).

The Mathematical Gamma Equation

For a reference evaluated point $r_m$ and calculated point $r_c$, the gamma value $\Gamma(r_m, r_c)$ is defined as: [ \Gamma(r_m, r_c) = \sqrt{ \left( \frac{\Delta D}{\Delta D_{\text{tol}}} \right)^2 + \left( \frac{r_m - r_c}{\text{DTA}_{\text{tol}}} \right)^2 } ] Where:

• $\Delta D$ is the dose difference between measured and calculated points.
• $\Delta D_{\text{tol}}$ is the dose difference tolerance criterion (e.g., 3%).
• $\text{DTA}_{\text{tol}}$ is the spatial distance-to-agreement criterion (e.g., 2 mm).

The minimum gamma index $\gamma(r_m)$ for point $r_m$ is determined across all calculated points:

• If $\gamma \le 1.0$, the point passes criteria.
• If $\gamma > 1.0$, the point fails criteria.

AAPM TG-218 Guidelines and Action Levels for IMRT Verification

In 2018, the AAPM published Task Group 218 (TG-218), standardizing IMRT QA measurement procedures, analysis methodologies, and passing rate thresholds across radiation oncology.

Key TG-218 Standards

• Universal Standard Gamma Criteria: 3% / 2 mm with Global Dose Normalization and a 10% Low-Dose Cutoff Threshold (eliminating background noise evaluation).
• Universal Passing Rate Tolerance: ≥95.0% of evaluated points must pass $\gamma \le 1.0$.
• Action Limit: Passing rate <90.0% requires mandatory plan hold, physics investigation, and plan re-optimization or delivery recalibration.

Measurement Devices for Pre-Treatment Verification

Patient-specific IMRT QA is executed by recalculating the patient plan onto a standardized phantom, delivering the plan on the linac, and measuring the resulting dose distribution with high-resolution detectors:

1. 2D Diode Arrays (e.g., Sun Nuclear MapCHECK): A planar array of n-type semiconductor diodes embedded in acrylic. Provides real-time dose measurement with high spatial resolution.
2. 2D Ion Chamber Arrays (e.g., PTW MatriXX): Arrays of micro-ionization chambers. Offers superior long-term stability and energy independence.
3. EPID Portal Dosimetry: Utilizes the linac's amorphous silicon flat-panel detector to capture transmitted beam fluence, providing high-resolution pixel matrices.
4. 3D Gel and Scintillator Detectors: True 3D volumetric dosimeters used for complex SRS/SBRT end-to-end testing.

In-Vivo Dosimetry Technologies

In-vivo dosimetry involves measuring dose directly on or inside the patient during actual treatment delivery. It serves as an ultimate safety check to detect setup errors, missing bolus, incorrect wedges, or R&V transfer errors.

Common In-Vivo Dosimeters

• Optically Stimulated Luminescent Dosimeters (OSLDs): Carbon-doped aluminum oxide ($ ext{Al}_2 ext{O}_3: ext{C}$) crystals. Trapped electrons are stimulated by green laser light, emitting blue light proportional to radiation dose. Reusable and highly accurate.
• Thermoluminescent Dosimeters (TLDs): Lithium fluoride (LiF) crystals. Trapped electrons are released by thermal heating, emitting light. Highly accurate but require labor-intensive reading cycles.
• Semiconductor Diodes: Instantaneous electronic readout, placed directly on skin.

In-Vivo Action Limits

The clinical action threshold for in-vivo skin dose agreement relative to TPS calculated surface dose is ±5.0%. Discrepancies exceeding 5% require setup re-verification, bolus inspection, and physics consultation.